BD PharmingenTM PE Mouse Anti-Human MIP-1alpha (CCL3)

Description

Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls. Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls. Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls. Show More Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls. Show More Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls. Flow cytometric analysis of MIP-1alpha CCL3 expression by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hr with LPS 10 ng/ml in the presence of GolgiStop Cat. No. 554724; aka monensin 2 muM . The PBMC were harvested, stained with FITC Mouse Anti-Human CD14 Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE Mouse Anti-Human MIP-1alpha CCL3 Cat. No. 554730 following Pharmingens staining protocol left panel . The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE Mouse Anti-Human MIP-1alpha CCL3 was blocked by the preincubation of the conjugated antibody with recombinant human MIP-1alpha 0.5 mug; middle panel , and by preincubation of the fixed/permeabilized cells with the unlabeled 11A3 antibody 5.0 mug, right panel prior to staining with the conjugate antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody right panel blocking specificity controls.